Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Equity Average (2022 - 2025)

Historic Equity Average for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $323.2 million.

  • Centessa Pharmaceuticals' Equity Average fell 1775.97% to $323.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $323.2 million, marking a year-over-year decrease of 1775.97%. This contributed to the annual value of $318.9 million for FY2024, which is 1142.11% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Equity Average stood at $323.2 million, which was down 1775.97% from $365.6 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Equity Average ranged from a high of $450.3 million in Q4 2024 and a low of $225.7 million during Q1 2024
  • Over the past 4 years, Centessa Pharmaceuticals' median Equity Average value was $338.9 million (recorded in 2022), while the average stood at $337.1 million.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Equity Average crashed by 3669.48% in 2023 and then surged by 8172.32% in 2024.
  • Centessa Pharmaceuticals' Equity Average (Quarter) stood at $354.5 million in 2022, then plummeted by 30.1% to $247.8 million in 2023, then surged by 81.72% to $450.3 million in 2024, then fell by 28.22% to $323.2 million in 2025.
  • Its Equity Average stands at $323.2 million for Q3 2025, versus $365.6 million for Q2 2025 and $393.9 million for Q1 2025.